264 related articles for article (PubMed ID: 25817328)
1. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
Kreher S; Jöhrens K; Strehlow F; Martus P; Borowiec K; Radke J; Heppner F; Roth P; Thiel E; Pietsch T; Weller M; Korfel A
Neuro Oncol; 2015 Jul; 17(7):1016-21. PubMed ID: 25817328
[TBL] [Abstract][Full Text] [Related]
2. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
3. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
4. [Effect of B Cell Differentiation Markers on the Prognosis of Primary Central Nervous System Lymphoma].
Chen XL; Li XY; Wang W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1410-1414. PubMed ID: 29070116
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
7. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome and prognostic factors in PCNSL.
Niparuck P; Boonsakan P; Sutthippingkiat T; Pukiat S; Chantrathammachart P; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Atichartakarn V
Diagn Pathol; 2019 Jun; 14(1):56. PubMed ID: 31189479
[TBL] [Abstract][Full Text] [Related]
10. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
[TBL] [Abstract][Full Text] [Related]
11. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
[TBL] [Abstract][Full Text] [Related]
12. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.
Bajwa AA; Khadim MT; Din HU; Ali SS; Jamil U; Khan UAS
J Coll Physicians Surg Pak; 2017 Oct; 27(10):621-624. PubMed ID: 29056123
[TBL] [Abstract][Full Text] [Related]
14. The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.
Lu TX; Miao Y; Wu JZ; Gong QX; Liang JH; Wang Z; Wang L; Fan L; Hua D; Chen YY; Xu W; Zhang ZH; Li JY
Sci Rep; 2016 Feb; 6():20465. PubMed ID: 26857366
[TBL] [Abstract][Full Text] [Related]
15. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
Ye ZY; Cao YB; Lin TY; Lin HL
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
[TBL] [Abstract][Full Text] [Related]
16. MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis.
Ge L; Lu S; Xu L; Yan H
Clin Neurol Neurosurg; 2021 Sep; 208():106838. PubMed ID: 34339901
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.
Ichiki A; Carreras J; Miyaoka M; Kikuti YY; Jibiki T; Tazume K; Watanabe S; Sasao T; Obayashi Y; Onizuka M; Ohmachi K; Yoshiba F; Shirasugi Y; Ogawa Y; Kawada H; Nakamura N; Ando K
J Clin Exp Hematop; 2017; 57(2):54-63. PubMed ID: 29021515
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].
Min M; Lin L; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):110-6. PubMed ID: 22780928
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
